Zhongguancun announced that its subsidiary Duoduo Pharmaceutical Co., Ltd. recently received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for ivabradine hydrochloride tablets) was accepted. Ivabradine hydrochloride tablets are suitable for patients with NYHA grade II to IV chronic heart failure with sinus rhythm and heart rate greater than 75 beats/minute, in combination with standard treatments including beta-blockers, or when treatment with beta-blockers is contraindicated or intolerable. As of the disclosure date of this announcement, the Ivabradine hydrochloride tablet project has invested a total of 3.642,800 yuan in R&D expenses.

Zhongguancun announced that its subsidiary Duoduo Pharmaceutical Co., Ltd. recently received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for ivabradine hydrochloride tablets) was accepted. Ivabradine hydrochloride tablets are suitable for patients with NYHA grade II to IV chronic heart failure with sinus rhythm and heart rate greater than 75 beats/minute, in combination with standard treatments including beta-blockers, or when treatment with beta-blockers is contraindicated or intolerable. As of the disclosure date of this announcement, the Ivabradine hydrochloride tablet project has invested a total of 3.642,800 yuan in R&D expenses.